Extracorporeal Photopheresis and Mogamulizumab for the Treatment of Erythrodermic Cutaneous T Cell Lymphoma
Plain-language summary
This trial is testing Extracorporeal Photopheresis for patients with cutaneous T-cell lymphoma (CTCL), including mycosis fungoides or Sézary syndrome at various stages of their disease. This is a Phase 2 trial, which means researchers are studying how well the treatment works and monitoring for side effects. Researchers want to learn whether this approach can help control the lymphoma. This trial is available at 3 locations in the United States. The trial is currently recruiting patients.
Who can join (key eligibility)
- Age 18 Years or older
- Must be well enough for treatment (adequate performance status)
Final eligibility is determined by the trial team. This list is a starting point only.
What's being tested
Extracorporeal Photopheresis (PROCEDURE): Undergo ECP | Mogamulizumab (BIOLOGICAL): Given IV | Quality-of-Life Assessment (OTHER): Ancillary studies | Questionnaire Administration (OTHER): Ancillary studies
Extracorporeal Photopheresis, Mogamulizumab, Quality-of-Life Assessment, Questionnaire Administration
- Treatment length
- Ask the trial team for details
- Visit frequency
- Ask the trial team for details